Anti-metabolites
Decitabine + JAK Inhibitors for Advanced Myeloproliferative Disorders
Recruiting1 awardPhase 2
Seattle, Washington
This trial looks at whether a combination of decitabine, ruxolitinib, and fedratinib may be more effective than chemotherapy or no treatment in patients with myeloproliferative neoplasms.
INCB057643 +/- Ruxolitinib for Myelofibrosis
Recruiting1 awardPhase 1
Birmingham, Alabama
This trial is testing a new drug called INCB057643, alone or with ruxolitinib, for patients with certain blood cancers like myelofibrosis. The goal is to see if it can stop cancer growth or help other treatments work better. Ruxolitinib has been approved for the treatment of myelofibrosis and has shown clinical benefits in reducing symptoms and improving survival.
JAK Inhibitor
MMB for Myelofibrosis
Recruiting1 awardPhase 2
Orange, California
This trial aims to provide ongoing access to momelotinib for patients with certain types of myelofibrosis who are already taking the drug and have not seen their disease get worse. The study will also look at how long these patients live without developing leukemia. Momelotinib has been studied for myelofibrosis and other related conditions.
Alkylating agents
Topotecan + Carboplatin + Veliparib for Leukemia
Recruiting1 awardPhase 2
Los Angeles, California
This trial is testing how well topotecan hydrochloride, carboplatin, and veliparib work in treating patients with myeloproliferative disorders and acute myeloid leukemia or chronic myelomonocytic leukemia.
Anti-metabolite
Ruxolitinib + Azacytidine for Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm
Recruiting1 awardPhase 2
Houston, Texas
This trial is testing two drugs, ruxolitinib phosphate and azacytidine, in patients with specific types of blood cancers that are hard to treat. Ruxolitinib blocks enzymes needed for cancer cell growth, while azacytidine kills cancer cells or stops them from dividing. Azacytidine is a well-known anticancer drug used in the treatment of various cancers, including breast cancer, melanoma, and colon cancer. The goal is to find a more effective treatment for these patients.
Popular Filters
Trials for Myelofibrosis Patients
Epigenetic Modulator
Bomedemstat for Blood Disorders
Recruiting2 awardsPhase 3
Ann Arbor, Michigan
"This trial aims to continue monitoring participants who have been taking bomedemstat for a while to gather information on its long-term safety and effectiveness. Participants must have been using bomedemstat for at
Histone Deacetylase Inhibitor
PXS-5505 for Myelofibrosis
Recruiting1 awardPhase 1 & 2
Birmingham, Alabama
This trial tests a new drug, PXS-5505, for safety and tolerance in patients with specific bone marrow disorders. It aims to find the best dose and see if combining it with another medication improves treatment.
JAK2 Inhibitor
Pacritinib for Myelofibrosis
Recruiting2 awardsPhase 3
Commack, New York
This trial is testing a new drug, pacritinib, to see if it is better than the current standard of care for treating patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis who have severe thrombocytopenia (low platelet count). 399 patients will be enrolled and randomly assigned to either pacritinib or the current standard of care. The primary outcome measure is spleen response rate.
Chemotherapy
INCB000928 + Ruxolitinib for Myelofibrosis
Recruiting1 awardPhase 1 & 2
Duarte, California
This trial is testing a new drug called INCB000928, either alone or with ruxolitinib, to see if it is safe and effective. It targets people with Myelofibrosis who need regular blood transfusions or have severe anemia. The goal is to see if the drug can reduce the need for transfusions and improve anemia symptoms.
Trials for ET Patients
Histone Methyltransferase Inhibitor
Bomedemstat vs Hydroxyurea for Essential Thrombocythemia
Recruiting1 awardPhase 3
Fort Wayne, Indiana
This trial aims to see if bomedemstat is better and safer than hydroxyurea for treating essential thrombocythemia. The main goal is to compare the two drugs based on their
Epigenetic Modulator
Bomedemstat for Blood Disorders
Recruiting2 awardsPhase 3
Ann Arbor, Michigan
"This trial aims to continue monitoring participants who have been taking bomedemstat for a while to gather information on its long-term safety and effectiveness. Participants must have been using bomedemstat for at
Interferon
Ropeginterferon Alfa-2b for Essential Thrombocythemia
Recruiting4 awardsPhase 3
Scottsdale, Arizona
This trial is testing a new drug, P1101, to see if it is more effective and has fewer side effects than the current standard drug, ANA, for treating people with essential thrombocythemia who have not responded well to hydroxyurea.
Phase 3 Trials
Histone Methyltransferase Inhibitor
Bomedemstat vs Hydroxyurea for Essential Thrombocythemia
Recruiting1 awardPhase 3
Fort Wayne, Indiana
This trial aims to see if bomedemstat is better and safer than hydroxyurea for treating essential thrombocythemia. The main goal is to compare the two drugs based on their
Epigenetic Modulator
Bomedemstat for Blood Disorders
Recruiting2 awardsPhase 3
Ann Arbor, Michigan
"This trial aims to continue monitoring participants who have been taking bomedemstat for a while to gather information on its long-term safety and effectiveness. Participants must have been using bomedemstat for at
Interferon
Ropeginterferon Alfa-2b for Essential Thrombocythemia
Recruiting4 awardsPhase 3
Scottsdale, Arizona
This trial is testing a new drug, P1101, to see if it is more effective and has fewer side effects than the current standard drug, ANA, for treating people with essential thrombocythemia who have not responded well to hydroxyurea.
JAK2 Inhibitor
Pacritinib for Myelofibrosis
Recruiting2 awardsPhase 3
Commack, New York
This trial is testing a new drug, pacritinib, to see if it is better than the current standard of care for treating patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis who have severe thrombocytopenia (low platelet count). 399 patients will be enrolled and randomly assigned to either pacritinib or the current standard of care. The primary outcome measure is spleen response rate.
Small Molecule Inhibitor
KRT-232 for Myelofibrosis
Recruiting1 awardPhase 2 & 3
Birmingham, Alabama
This trial will study KRT-232, a new drug that inhibits MDM2, for the treatment of patients with myelofibrosis who are no longer benefiting from treatment with a JAK inhibitor. The trial will be conducted in 2 phases.
Trials With No Placebo
Epigenetic Modulator
Bomedemstat for Blood Disorders
Recruiting2 awardsPhase 3
Ann Arbor, Michigan
"This trial aims to continue monitoring participants who have been taking bomedemstat for a while to gather information on its long-term safety and effectiveness. Participants must have been using bomedemstat for at
Histone Deacetylase Inhibitor
PXS-5505 for Myelofibrosis
Recruiting1 awardPhase 1 & 2
Birmingham, Alabama
This trial tests a new drug, PXS-5505, for safety and tolerance in patients with specific bone marrow disorders. It aims to find the best dose and see if combining it with another medication improves treatment.
Interferon
Ropeginterferon Alfa-2b for Essential Thrombocythemia
Recruiting4 awardsPhase 3
Scottsdale, Arizona
This trial is testing a new drug, P1101, to see if it is more effective and has fewer side effects than the current standard drug, ANA, for treating people with essential thrombocythemia who have not responded well to hydroxyurea.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.